Toggle Nav
Close
  • Menu
  • Setting

Anti-IL-13 Antibody (Cendakimab)

Catalog No.
F1270
Anti-IL-13 Antibody (Cendakimab)
Grouped product items
SizePriceStock Qty
100ug
$75.00
Ship with 3-5 days
1mg
$225.00
Ship with 3-5 days
5mg
$630.00
Ship with 3-5 days
50mg
$2,111.00
Ship with 3-5 days
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized recombinant monoclonal antibody against IL-13. Cendakimab has high affinity and potency for human wild-type and variant IL-13 and blocks the binding of IL-13 to IL-13Rα1 and IL-13Rα2 with IC50 of 352 pM and 631 pM, respectively, as determined by ELISA. Cendakimab recognizes wild-type human IL-13 and the common polymorphic variant R110Q with binding potencies of 52 pM and 50 pM, respectively. Cendakimab has the potential to be used in IL-13-related allergic/inflammatory diseases such as asthma and eosinophilic esophagitis.

Quality Control

Quality Control & DataSheet

View current batch:
 

M.Wt

145 kDa

Shipping

Dry ice

Cas No.

2151032-62-9

Storage

-80°C

Expiration Date

2 years

Form

Liquid

Concentration

See label

Reconstitution

For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.

Host

CHO

Alternative Names

ABT-308, 13C5.5, RPC4046

Buffer System

100 mM Pro 20 mM Arg pH 5.0. No preservative!

Target Accession

P35225

Reactivity

Human

Conjugation

Unconjugated

Clonality

Monoclonal

Purification

Protein A

Isotype

IgG1

Application

ELISA, FACS, Kinetics, Functional assay, Animal Model

Target

IL-13

Note

Please avoid freeze-thaw cycles.